)
)
)
Halia Therapeutics is a clinical-stage biotechnology company developing first-in-class therapies that target inflammation at its source. Our pipeline is built on a deep understanding of genetic resilience—natural human mutations that protect against disease by shutting down harmful inflammatory pathways. HT-6184, our lead program, is an oral NEK7/NLRP3 inflammasome modulator with compelling Phase 2 data in myelodysplastic syndromes (MDS). In partnership with UAE national genomics initiatives. HT-4253, our LRRK2 inhibitor, is advancing toward a precision-medicine Phase 2 in genetically defined early Alzheimer’s disease. We operate across the U.S. and the Middle East, leveraging global clinical networks, genetic databases, and regulatory pathways to accelerate therapeutic development in inflammation-driven diseases.
Year Founded
2017
Next catalyst (value inflection) update
Phase II data maturation and regulatory milestones for HT-6184 (Ofirnoflast), including advancement toward pivotal development in MDS and continued expansion of strategic partnering discussions.
Expected time of next catalyst update
Mar-26
City
Lehi
Country
United States
Company CEO or top company official
Dr. David Bearss PhD
Development Phase of Primary Product
Phase II
Lead Product in Development
HT-6184 (Ofirnoflast) — a first-in-class, oral NEK7 / NLRP3 inflammasome modulator being developed as a disease-modifying therapy, with lead programs in myelodysplastic syndromes (MDS) and metabolic disease.
Number of Unlicensed Products
2 clinical and 2 pre-clinical
Therapeutic Area
Inflammation
Website
http://www.haliatx.com
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
